提示: 手机请竖屏浏览!

2型糖尿病的血糖控制
Glycemic Management of Type 2 Diabetes Mellitus


Faramarz Ismail-Beigi ... 糖尿病 • 2012.04.05
相关阅读
• 全谷物食品与餐后血糖的关系 • 老年糖尿病患者的血糖管理是否过强 • 2型糖尿病的糖化血红蛋白控制目标:美国内科医师学会的指导声明 • 2型糖尿病的门诊和住院治疗

杂志的这一部分首先引入一个病例摘要来强调一个常见的临床问题,然后提出有证据支持的各种策略。如果存在正式的指南,作者则对此进行综述。文章以作者的临床推荐建议结尾。

 

一位39岁男性患者前来就诊,他有2年的2型糖尿病病史,没有微血管或大血管并发症。他的母亲和哥哥患有2型糖尿病和心血管疾病。经检查,他的体重是99.8 kg(220 lb),体质指数(BMI,体重的千克数除以身高米数的平方)为37,血压是125/85 mmHg。他的糖化血红蛋白水平为8.9%,血清肌酐水平为1 mg/dL(88.4 μmol/L),低密度脂蛋白(LDL)胆固醇为88 mg/dL(2.3 mmol/L),高密度脂蛋白(HDL)胆固醇为45 mg/dL(1.2 mmol/L),甘油三酯为130 mg/dL(1.5 mmol/L);并且未检测出微量白蛋白尿。他的治疗药物包括二甲双胍(每次500 mg,每天2次),格列吡嗪(每次5 mg,每天2次),辛伐他汀(每天20 mg),赖诺普利(每天10 mg)。你会建议如何改善他的血糖控制?





作者信息

Faramarz Ismail-Beigi, M.D., Ph.D.
From the Department of Medicine, University Hospitals and Veterans Affairs Medical Center, Case Western Reserve University, Cleveland. Address reprint requests to Dr. Ismail-Beigi at the Department of Medicine, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106-4951, or at fxi2@case.edu.

 

参考文献

1. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-2222[Erratum, Lancet 2010;376:958.]

2. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta: Department of Health and Human Services, Centers for Disease Control and Prevention, 2011 (http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf).

3. Narayan KM, Ali MK, Koplan JP. Global noncommunicable disease -- where worlds meet. N Engl J Med 2010;363:1196-1198

4. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011;378:182-197

5. DeFronzo R. From the triumvirate to the ominous octet: a new paradigm for the treatment of type diabetes mellitus. Diabetes 2009;58:773-795

6. American Diabetes Association. Standards of medical care in diabetes -- 2012. Diabetes Care 2012;35:Suppl 1:S11-S63

7. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-110

8. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008;10:Suppl 4:32-42

9. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-794

10. UK. Prospective Diabetes Study Group. U.K. prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-1258[Erratum, Diabetes 1996;45:1655.]

11. Voight BF, Scott LJ, Steinthorsdottir V, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010;42:579-589

12. Gaede P, Lund-Anderson H, Parving HH, Pedersen O. Effect of multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591

13. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986

14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853

15. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139

16. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572

17. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-244

18. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-430

19. Holman RR, Paul SK, Bethel M, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589

20. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559

21. Nathan DM, Buse JB, Davidson MB, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203

22. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract 2011;17:287-302

23. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a metaanalysis. Diabetes Care 2008;31:2383-2390

24. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1c assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478

25. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003;26:1485-1489

26. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009;301:1565-1572

27. de Galan BE, Zoungas S, Chalmers J, et al. Cognitive function and risks of cardiovascular disease in hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia 2009;52:2328-2336

28. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011;154:554-559

29. Management of diabetes mellitus in primary care. Washington, DC: Department of Veterans Affairs, 2010 (http://www.healthquality.va.gov/diabetes_mellitus.asp).

30. Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets: a guidance statement from the American College of Physicians. Ann Intern Med 2007;147:417-422

31. Ralston JD, Hirsch IB, Hoath J, Mullen M, Cheadle A, Goldberg HI. Web-based collaborative care for type 2 diabetes: a pilot randomized trial. Diabetes Care 2009;32:234-239

32. Wennberg DE, Marr A, Lang L, O'Malley S, Bennett G. A randomized trial of a telephone care-management strategy. N Engl J Med 2010;363:1245-1255

33. Wolfram T, Ismail-Beigi F. Efficacy of high-fiber diets in the management of type 2 diabetes. Endocr Pract 2011;17:132-142

34. Bolen S, Feldman L, Vassy J, et al. Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007;147:386-399

35. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443

36. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-1747

37. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-1573

38. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-613

39. Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review. Diabetes Res Clin Pract 2011;92:1-10

40. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2012;156:218-231

41. Hung AM, Roumie CL, Greevy RA, et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int 2012 January 18 (Epub ahead of print).

42. Davis SN, Wei W, Garg S. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract 2011;17:845-852

43. Wilcox R, Kupfer S, Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 2008;155:712-717

44. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471

45. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 2004;47:969-975

46. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. Diabet Med 2006;23:736-742

47. Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012;307:56-65

48. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:248-256

49. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery vs. conventional medical therapy for type 2 diabetes. N Engl J Med 2012. DOI: 10.1056/NEJMoa1200111.

50. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery vs. medical therapy in obese patients with diabetes. N Engl J Med 2012. DOI: 10.1056/NEJMoa1200225.

51. Nyalakonda K, Sharma T, Ismail-Beigi F. Preservation of beta-cell function in type 2 diabetes. Endocr Pract 2010;16:1038-1055

52. Leahy JL, Hirsch IB, Peterson KA, Schneider D. Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab 2010;95:4206-4216

53. Bennett WL, Odelola OA, Wilson LM, et al. Evaluation of guideline recommendations on oral medication for type 2 diabetes mellitus: a systematic review. Ann Intern Med 2012;156:27-36

54. Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13:Suppl 1:1-68

服务条款 | 隐私政策 | 联系我们